ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1870

Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients

Belén Atienza-Mateo1, Iván Ferraz-Amaro2, Emma Beltrán Catalán3, Alfredo Adán4, Marisa Hernandez Garfella5, Lucía Martínez-Costa6, Miguel Cordero Coma7, Manuel Diaz-Llopis8, José M. Herreras9, Ana Blanco10, Ignacio Torre11, David Díaz-Valle12, Antonio Atanes-Sandoval13, Felix Hernandez14, Santos Insua15, Julio Sánchez16, raquel almodovar17, Oscar Ruiz-Moreno18, Myriam Gandia Martinez19, Joan M. Nolla20, José Luis Martin-Varillas21, Vanesa Calvo-Río22, Diana Prieto-Peña23, Miguel Ángel gonzalez-Gay24 and Ricardo Blanco22, 1Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 3Hospital del Mar, Barcelona, Spain, 4Hospital Clinic, Barcelona, Spain, 5Hospital General Universitario de Valencia, Valencia, Spain, 6Hospital Peset, Valencia, Valencia, Spain, 7Hospital de León, Leon, Spain, 8Hospital Universitario La Fe, Valencia, Spain, 9Hospital Universitario IOBA, Valladolid, Spain, 10Hospital Universitario de Donostia, San Sebastián, 11Hospital Universitario de Basurto, Bilbao, Spain, 12Hospital Clínico San Carlos, Madrid, Madrid, Spain, 13Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, 14Hospital Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain, 15Hospital Universitario Santiago de Compostela, A Coruña, Spain, 16Hospital Universitario 12 de Octubre, Madrid, Spain, 17Hospital Universitario Fundación de Alcorcón, Madrid, Spain, 18Hospital Universitario Miguel Servet, Zaragoza, Zaragoza, Spain, 19Hospital Puerta del Mar, Cádiz, Spain, 20Hospital Universitario de Bellvitge, Barcelona, Barcelona, Spain, 21Hospital Sierrallana, Torrelavega, Spain, 22Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 23Hospital Universitario Marqués de Valdecilla, santander, Spain, 24Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Meeting: ACR Convergence 2021

Keywords: Anti-TNF Drugs, Behçet's Syndrome, Cystoid Macular Edema, Tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Posterior segment involvement is the most serious affection of uveitis in Behçet’s disease (BD), with cystoid macular edema (CME) being the leading cause of blindness. Anti-TNF, especially adalimumab (ADA) and infliximab (IFX), have demonstrated efficacy as first-line biologic agents in BD-related uveitis [Arthritis Rheumatol. 2019;71(12):2081-2089; Ophthalmology. 2018;125(9):1444-1451]. Moreover, the anti-IL6R tocilizumab (TCZ) has shown excellent results in highly refractory BD-uveitis and noninfectious uveitic CME [Rheumatology (Oxford). 2018;57(5):856-864; Am J Ophthalmol.2019;200:85-94; Clin Exp Rheumatol. 2014;32(4 Suppl 84): S54-7; Clin Exp Rheumatol. 2016;34(6 Suppl 102): S34-S40. Our aim was to compare the efficacy of ADA vs IFX vs TCZ in patients with refractory CME due to BD.

Methods: Observational multicenter study of patients with BD-associated CME refractory to conventional and/or biological immunosuppressive drugs. From a cohort of 177 patients treated with anti-TNF and 14 patients treated with TCZ, we selected those with CME at baseline. CME was defined as macular thickness > 300μm (measured by optic coherence tomography). We analyzed in the 3 groups of treatment (ADA, IFX, TCZ) from baseline up to 4 years the evolution of macular thickness (main outcome), best-corrected visual acuity (BCVA) and intraocular inflammation (Tyndall and vitritis). Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the 3 groups.

Results: A total of 49 patients were included. ADA was used in 25 patients (40 eyes with CME), IFX in 15 (21 eyes with CME) and TCZ in 9 (11 eyes with CME). Thus, a sum of 72 affected eyes was analyzed. No statistically significant baseline differences were observed between the 3 groups (Table 1) except for a lower basal BCVA in patients treated with TCZ and a higher basal degree of intraocular inflammation in patients treated with ADA. Most patients from all groups had received several conventional immunosuppressive drugs. In addition, most patients in the group of TCZ had also received anti-TNF (5 patients received ADA, 1 received IFX and 2 received both ADA and IFX, in different times). Biological therapy was used in monotherapy or combined with azathioprine (n=10, 5 and 1 in ADA, IFX and TCZ group, respectively), cyclosporine A (n=10, 5 and 1) or methotrexate (n=4, 2 and 3). Macular thickness progressively decreased in the 3 groups, with no signs of CME after 1 year of treatment (Figure 1). Similarly, BCVA improvement and inflammatory ocular remission was reached in all groups.

Conclusion: Refractory CME associated to BD’s uveitis can be effectively treated with ADA, IFX or TCZ. Moreover, TCZ is effective in patients resistant to anti-TNF therapy.

Table 1. Demographic and clinical characteristics of 49 patients with cystoid macular edema due to Behçet’s disease receiving ADA, IFX or TCZ. Data are presented as mean ± SD or median (IQR) when data were not normally distributed. ADA, adalimumab; BCVA, best corrected visual acuity; CME, cystic macular edema; IFX, infliximab; TCZ, tocilizumab.

Figure 1. Evolution of ocular parameters in 49 patients with cystoid macular edema due to Behçet’s disease receiving ADA, IFX or TCZ.


Disclosures: B. Atienza-Mateo, None; I. Ferraz-Amaro, None; E. Beltrán Catalán, None; A. Adán, None; M. Hernandez Garfella, None; L. Martínez-Costa, None; M. Cordero Coma, None; M. Diaz-Llopis, None; J. Herreras, None; A. Blanco, None; I. Torre, None; D. Díaz-Valle, None; A. Atanes-Sandoval, None; F. Hernandez, None; S. Insua, None; J. Sánchez, None; r. almodovar, None; O. Ruiz-Moreno, None; M. Gandia Martinez, None; J. Nolla, None; J. Martin-Varillas, None; V. Calvo-Río, None; D. Prieto-Peña, None; M. gonzalez-Gay, None; R. Blanco, Brystol Myers Squibb, 6.

To cite this abstract in AMA style:

Atienza-Mateo B, Ferraz-Amaro I, Beltrán Catalán E, Adán A, Hernandez Garfella M, Martínez-Costa L, Cordero Coma M, Diaz-Llopis M, Herreras J, Blanco A, Torre I, Díaz-Valle D, Atanes-Sandoval A, Hernandez F, Insua S, Sánchez J, almodovar r, Ruiz-Moreno O, Gandia Martinez M, Nolla J, Martin-Varillas J, Calvo-Río V, Prieto-Peña D, gonzalez-Gay M, Blanco R. Comparative Study on Anti-TNF vs Tocilizumab for Treatment of Refractory Uveitic Cystoid Macular Edema Due to Behcet’s Disease: Multicenter Study of 49 Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/comparative-study-on-anti-tnf-vs-tocilizumab-for-treatment-of-refractory-uveitic-cystoid-macular-edema-due-to-behcets-disease-multicenter-study-of-49-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparative-study-on-anti-tnf-vs-tocilizumab-for-treatment-of-refractory-uveitic-cystoid-macular-edema-due-to-behcets-disease-multicenter-study-of-49-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology